{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:07:21Z","timestamp":1757311641244,"version":"3.41.2"},"reference-count":53,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T00:00:00Z","timestamp":1582675200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Cardiol"],"abstract":"<jats:p>Percutaneous revascularisation has evolved dramatically in the past few decades. The approach to the management of ischaemic heart disease has changed due to the development of new devices and techniques as well as the availability of new drugs and treatment strategies. Its use in combination with antiplatelet therapies has been essential to protect against stent thrombosis. The length of time this combination therapy is used has been modified in recent years and has been the subject of extensive research. The effect of prolonging the time it is taken or shortening it has been evaluated in different clinical conditions. In practice, the decisions regarding antithrombotic therapy after percutaneous coronary intervention are informed by the patient\u2019s profile and the characteristics of the procedures performed. In this article, we review the use of antiplatelet\/anticoagulant therapy after percutaneous coronary intervention focusing on trials and guidelines addressing variable durations for combination regimens and the alternatives.<\/jats:p>","DOI":"10.15420\/ecr.2019.25.2","type":"journal-article","created":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T11:54:58Z","timestamp":1582890898000},"source":"Crossref","is-referenced-by-count":3,"title":["Antithrombotic Treatment After Coronary Intervention: Agreement and Controversy"],"prefix":"10.15420","volume":"15","author":[{"given":"Tamara","family":"Garc\u00eda Camarero","sequence":"first","affiliation":[{"name":"Department of Interventional Cardiology, Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 M","family":"de la Torre Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Department of Interventional Cardiology, Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6096","published-online":{"date-parts":[[2020,2,26]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084\u20139. https:\/\/doi.org\/10.1056\/NEJM199604253341702; PMID: 8598866.","DOI":"10.1056\/nejm199604253341702"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Bertrand ME, Rupprecht HJ, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 2000;102:624\u20139. https:\/\/doi.org\/10.1161\/01.CIR.102.6.624; PMID: 10931801.","DOI":"10.1161\/01.cir.102.6.624"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007;369:667\u201378. https:\/\/doi.org\/10.1016\/S0140-6736(07)60314-6; PMID: 17321312.","DOI":"10.1016\/s0140-6736(07)60314-6"},{"key":"ref3","unstructured":"de la Torre-Hern\u00e1ndez JM, Alfonso F, Hern\u00e1ndez F, et al. ESTROFA Study Group. Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Spanish Study on Thrombosis of Pharmacoactive stents). J Am Coll Cardiol 2008;51:986\u201390. https:\/\/doi.org\/10.1016\/j.jacc.2007.10.057; PMID: 18325436."},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356:1020\u20139. https:\/\/doi.org\/10.1056\/NEJMoa067731; PMID: 17296821.","DOI":"10.1056\/nejmoa067731"},{"key":"ref5","unstructured":"Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012;379:1393\u2013402. https:\/\/doi.org\/10.1016\/S0140-6736(12)60324-9; PMID: 22445239."},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Bangalore S, Toklu B, Amoroso N, et al. Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. Br Med J 2013;347:f6625. https:\/\/doi.org\/10.1136\/bmj.f6625; PMID: 24212107.","DOI":"10.1136\/bmj.f6625"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527\u201333. https:\/\/doi.org\/10.1016\/S0140-6736(01)05701-4; PMID: 11520521.","DOI":"10.1016\/s0140-6736(01)05701-4"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411\u201320. https:\/\/doi.org\/10.1001\/jama.288.19.2411; PMID: 12435254.","DOI":"10.1001\/jama.288.19.2411"},{"key":"ref9","unstructured":"Levine GN, Bates ER, Bittl JA, et al. ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2016;68:1082\u2013115. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.513; PMID: 27036918."},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Bittl JA, Baber U, Bradley SM, et al. Duration of dual antiplatelet therapy: a systematic review for the 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;68:1116\u201339. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.512; PMID: 27036919.","DOI":"10.1016\/j.jacc.2016.03.512"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018;39:213\u201360. https:\/\/doi.org\/10.1093\/eurheartj\/ehx419. PMID: 28886622.","DOI":"10.1093\/eurheartj\/ehx419"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Gwon HC, Hahn JY, Park KW, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience\/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 2012;125:505\u201313. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.059022; PMID: 22179532.","DOI":"10.1161\/circulationaha.111.059022"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Valgimigli M, Campo G, Monti M, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 2012;125:2015\u201326. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.071589; PMID: 22438530.","DOI":"10.1161\/circulationaha.111.071589"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Schulz-Sch\u00fcpke S, Byrne RA, Ten Berg JM, et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J 2015;36:1252\u201363. https:\/\/doi.org\/10.1093\/eurheartj\/ehu523; PMID: 25616646.","DOI":"10.1093\/eurheartj\/ehu523"},{"key":"ref15","unstructured":"Gilard M, Barragan P, Noryani AA, et al. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. J Am Coll Cardiol 2015;65:777\u201386. https:\/\/doi.org\/10.1016\/j.jacc.2014.11.008; PMID: 25461690."},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Colombo A, Chieffo A, Frasheri A, et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol 2014;64:2086\u201397. https:\/\/doi.org\/10.1016\/j.jacc.2014.09.008; PMID: 25236346.","DOI":"10.1016\/j.jacc.2014.09.008"},{"key":"ref17","unstructured":"Kim BK, Hong MK, Shin DH, et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET trial (REal safety and efficacy of 3 month dual antiplatelet therapy following endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 2012;60:1340\u20138.https:\/\/doi.org\/10.1016\/j.jacc.2012.06.043; PMID: 22999717."},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Feres F, Costa RA, Abizaid A, et al. Three vs. twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 2013;310:2510\u201322. https:\/\/doi.org\/10.1001\/jama.2013.282183; PMID: 24177257.","DOI":"10.1001\/jama.2013.282183"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Palmerini T, Benedetto U, Bacchi-Reggiani L, et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet 2015;385:2371\u201382. https:\/\/doi.org\/10.1016\/S0140-6736(15)60263-X; PMID: 25777667.","DOI":"10.1016\/s0140-6736(15)60263-x"},{"key":"ref20","unstructured":"Mauri L, Kereiakes DJ, Yeh RW et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371:2155\u201366. https:\/\/doi.org\/10.1056\/NEJMoa1409312; PMID: 25399658."},{"key":"ref21","unstructured":"Lee CW, Ahn JM, Park DW et al. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Circulation 2014;129:304\u201312. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.003303; PMID: 24097439."},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Collet JP, Silvain J, Barth\u00e9l\u00e9my O et al. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet 2014;384:1577\u201385. https:\/\/doi.org\/10.1016\/S0140-6736(14)60612-7; PMID: 25037988.","DOI":"10.1016\/s0140-6736(14)60612-7"},{"key":"ref23","unstructured":"Costa F, van Klaveren D, James S, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 2017;389:1025\u201334. https:\/\/doi.org\/10.1016\/S0140-6736(17)30397-5; PMID: 28290994."},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001\u201315. https:\/\/doi.org\/10.1056\/NEJMoa0706482; PMID: 17982182.","DOI":"10.1056\/nejmoa0706482"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045\u201357. https:\/\/doi.org\/10.1056\/NEJMoa0904327; PMID: 19717846.","DOI":"10.1056\/nejmoa0904327"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Kedhi E, Fabris E, van der Ent M, et al. Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial. Br Med J 2018;363:k3793. https:\/\/doi.org\/10.1136\/bmj.k3793; PMID: 30279197.","DOI":"10.1136\/bmj.k3793"},{"key":"ref27","unstructured":"Verdoia M, Kedhi E, Ceccon C, et al. Duration of dual antiplatelet therapy and outcome in patients with acute coronary syndrome undergoing percutaneous revascularization: A meta-analysis of 11 randomized trials. Int J Cardiol 2018;264:30\u20138. https:\/\/doi.org\/10.1016\/j.ijcard.2018.02.095; PMID: 29776573."},{"key":"ref28","unstructured":"Hahn JY, Song YB, Oh JH, et al. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Lancet 2018;391:1274\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(18)30493-8; PMID: 29544699."},{"key":"ref29","unstructured":"Hahn JY, Song YB, Oh JH, et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. JAMA 2019;321:2428\u201337. https:\/\/doi.org\/10.1001\/jama.2019.8146; PMID: 31237645."},{"key":"ref30","unstructured":"Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372:1791\u2013800. https:\/\/doi.org\/10.1056\/NEJMoa1500857; PMID: 25773268."},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Udell JA, Bonaca MP, Collet JP, et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J 2016;37:390\u20139. https:\/\/doi.org\/10.1093\/eurheartj\/ehv443; PMID: 26324537.","DOI":"10.1093\/eurheartj\/ehv443"},{"key":"ref32","unstructured":"Urban P, Mehran R, Colleran R, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation 2019;140:240\u201361. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.040167; PMID: 31116032."},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Palmerini T, Della Riva D, Benedetto U, et al. Three, six or twelve months of dual antiplatelet therapy after drug-eluting stent implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients. Eur Heart J 2017;38:1034\u201343. https:\/\/doi.org\/10.1093\/eurheartj\/ehw627; PMID: 28110296.","DOI":"10.1093\/eurheartj\/ehw627"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Urban P, Meredith IT, Abizaid A, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med 2015;373:2038\u201347. https:\/\/doi.org\/10.1056\/NEJMoa1503943; PMID: 26466021.","DOI":"10.1056\/nejmoa1503943"},{"key":"ref35","unstructured":"Sibbing D, Aradi D, Jacobshagen C, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet 2017;390:1747\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(17)32155-4; PMID: 28855078."},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Cuisset T, Deharo P, Quilici J, et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J 2017;38:3070\u20138. https:\/\/doi.org\/10.1093\/eurheartj\/ehx175; PMID: 28510646.","DOI":"10.1093\/eurheartj\/ehx175"},{"key":"ref37","unstructured":"Angiolillo DJ, Rollini F, Storey RF, et al. International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies. Circulation 2017;136:1955\u201375. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.031164; PMID: 29084738."},{"key":"ref38","unstructured":"Vranckx P, Valgimigli M, J\u00fcni P, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet 2018;392:940\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(18)31858-0; PMID: 30166073."},{"key":"ref39","unstructured":"Watanabe H, Domei T, Morimoto T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: The STOPDAPT-2 randomized clinical trial. JAMA 2019;321:2414\u201327. https:\/\/doi.org\/10.1001\/jama.2019.8145; PMID: 31237644."},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013;381:1107\u201315. https:\/\/doi.org\/10.1016\/S0140-6736(12)62177-1; PMID: 23415013.","DOI":"10.1016\/s0140-6736(12)62177-1"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Gibson CM, Mehran R, Bode C. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J 2015;169:472\u20138.e5. https:\/\/doi.org\/10.1016\/j.ahj.2014.12.006; PMID: 25819853.","DOI":"10.1016\/j.ahj.2014.12.006"},{"key":"ref42","unstructured":"Fiedler KA, Maeng M, Mehilli J, et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE Trial. J Am Coll Cardiol 2015;65:1619\u201329. https:\/\/doi.org\/10.1016\/j.jacc.2015.02.050; PMID: 25908066."},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017;377:1513\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1708454; PMID: 28844193.","DOI":"10.1056\/nejmoa1708454"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Golwala HB, Cannon CP, Steg PG, et al. Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. Eur Heart J 2018;39:1726\u201335a. https:\/\/doi.org\/10.1093\/eurheartj\/ehy162; PMID :29668889.","DOI":"10.1093\/eurheartj\/ehy162"},{"key":"ref45","unstructured":"Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or pci in atrial fibrillation. N Engl J Med 2019;380:1509\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1817083; PMID: 30883055."},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Vranckx P, Valgimigli M, Eckardt L. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet 2019;394:1335\u201343. https:\/\/doi.org\/10.1016\/S0140-6736(19)31872-0; PMID: 31492505.","DOI":"10.1016\/s0140-6736(19)31872-0"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Angiolillo DJ, Goodman SG, Bhatt DL, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention. Circulation 2018;138:527\u201336. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034722; PMID: 30571525.","DOI":"10.1161\/circulationaha.118.034722"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Matsumura-Nakano Y, Shizuta S, Komasa A, et al. Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation. Circulation 2019;139:604\u201316. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.036768; PMID: 30586700.","DOI":"10.1161\/circulationaha.118.036768"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Hong SJ, Shin DH, Kim JS, et al. 6-month versus 12-month dual-antiplatelet therapy following long everolimus-eluting stent implantation: The IVUS-XPL randomized clinical trial. JACC Cardiovasc Interv 2016;9:1438\u201346. https:\/\/doi.org\/10.1016\/","DOI":"10.1016\/j.jcin.2016.04.036"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"j.jcin.2016.04.036; PMID: 27212028.","DOI":"10.1088\/1475-7516\/2016\/04\/036"},{"key":"ref51","unstructured":"Nakamura M, Iijima R, Ako J, et al. Dual antiplatelet therapy for 6 versus 18 months after biodegradable polymer drug-eluting stent implantation. JACC Cardiovasc Interv 2017;10:1189\u201398. https:\/\/doi.org\/10.1016\/j.jcin.2017.04.019; PMID: 28641838."},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Helft G, Steg PG, Le Feuvre C, et al. Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial. Eur Heart J 2016;37:365\u201374. https:\/\/doi.org\/10.1093\/eurheartj\/ehv481; PMID: 26364288.","DOI":"10.1093\/eurheartj\/ehv481"}],"container-title":["European Cardiology Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2019.25.2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T15:59:35Z","timestamp":1613836775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2019.25.2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,26]]},"references-count":53,"URL":"https:\/\/doi.org\/10.15420\/ecr.2019.25.2","relation":{},"ISSN":["1758-3764","1758-3756"],"issn-type":[{"type":"electronic","value":"1758-3764"},{"type":"print","value":"1758-3756"}],"subject":[],"published":{"date-parts":[[2020,2,26]]},"article-number":"e07"}}